Anti-NBEA/ BCL8B/ LYST2 monoclonal antibody

Anti-NBEA/ BCL8B/ LYST2 antibody for FACS & in-vivo assay

Target products collectionGo to NBEA/NBEA products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)


Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-MP0864-Ab-1/ GM-Tg-hg-MP0864-Ab-2Anti-Human NBEA monoclonal antibodyHuman
GM-Tg-rg-MP0864-Ab-1/ GM-Tg-rg-MP0864-Ab-2Anti-Rat NBEA monoclonal antibodyRat
GM-Tg-mg-MP0864-Ab-1/ GM-Tg-mg-MP0864-Ab-2Anti-Mouse NBEA monoclonal antibodyMouse
GM-Tg-cynog-MP0864-Ab-1/ GM-Tg-cynog-MP0864-Ab-2Anti-Cynomolgus/ Rhesus macaque NBEA monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-MP0864-Ab-1/ GM-Tg-felg-MP0864-Ab-2Anti-Feline NBEA monoclonal antibodyFeline
GM-Tg-cang-MP0864-Ab-1/ GM-Tg-cang-MP0864-Ab-2Anti-Canine NBEA monoclonal antibodyCanine
GM-Tg-bovg-MP0864-Ab-1/ GM-Tg-bovg-MP0864-Ab-2Anti-Bovine NBEA monoclonal antibodyBovine
GM-Tg-equg-MP0864-Ab-1/ GM-Tg-equg-MP0864-Ab-2Anti-Equine NBEA monoclonal antibodyEquine

Size: 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-MP0864-Ab-1/ GM-Tg-hg-MP0864-Ab-2; GM-Tg-rg-MP0864-Ab-1/ GM-Tg-rg-MP0864-Ab-2;
GM-Tg-mg-MP0864-Ab-1/ GM-Tg-mg-MP0864-Ab-2; GM-Tg-cynog-MP0864-Ab-1/ GM-Tg-cynog-MP0864-Ab-2;
GM-Tg-felg-MP0864-Ab-1/ GM-Tg-felg-MP0864-Ab-2; GM-Tg-cang-MP0864-Ab-1/ GM-Tg-cang-MP0864-Ab-2;
GM-Tg-bovg-MP0864-Ab-1/ GM-Tg-bovg-MP0864-Ab-2; GM-Tg-equg-MP0864-Ab-1/ GM-Tg-equg-MP0864-Ab-2
Products NameAnti-NBEA monoclonal antibody
Formatmab
Target NameNBEA
Protein Sub-locationTransmembrane Protein
Category of antibodyFACS/Biofunctional Antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)
IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD).
TagFc
Products descriptionPre-made anti-NBEA benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenProducts DevelopingMulti-species NBEA/ BCL8B/ LYST2 VLP (virus-like particle) (Products Developing)


    Target information

    Target IDGM-MP0864
    Target NameNBEA
    Gene ID26960,26422,361948,714386,477305,101088046,525624,100065416
    Gene Symbol and SynonymsBCL8B,LYST2,mKIAA1544,NBEA,NEDEGE,RGD1562629
    Uniprot AccessionQ8NFP9
    Uniprot Entry NameNBEA_HUMAN
    Protein Sub-locationTransmembrane Protein
    Category
    DiseaseN/A
    Gene EnsemblENSG00000172915
    Target ClassificationN/A

    The target: NBEA, gene name: NBEA, also named as BCL8B, LYST2. This gene encodes a member of a large, diverse group of A-kinase anchor proteins that target the activity of protein kinase A to specific subcellular sites by binding to its type II regulatory subunits. Brain-specific expression and coat protein-like membrane recruitment of a highly similar protein in mouse suggest an involvement in neuronal post-Golgi membrane traffic. Mutations in this gene may be associated with a form of autism. This gene and its expression are frequently disrupted in patients with multiple myeloma. Alternative splicing results in multiple transcript variants encoding distinct isoforms. Additional transcript variants may exist, but their full-length nature has not been determined.[provided by RefSeq, Feb 2011].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.